CD38 inhibitor 1是一种强效的CD38抑制剂，对小鼠CD38的IC50值为1.9nM。
Cas No.:1700637-55-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CD38 inhibitor 1 is a potent CD38 inhibitor with an IC50 value of 1.9nM for mouse CD38 [1]. CD38 inhibitor 1 can increase the level of NAD+, thereby activating various factors related to longevity and healthy lifespan, such as sirtuins, AMPK, and PARPs, to prevent metabolic dysfunction [2]. The CD38 inhibitor 1 has been widely used to protect the heart from damage caused by ischemic injury to endothelial cells and cardiomyocytes[3].
In vitro, CD38 inhibitor 1 treatment (1µM) for 14 days upregulated the expression of Col2 and aggrecan mRNA and promoted the differentiation of mouse chondrocytes[4]. Treatment with 50µM CD38 inhibitor 1 for 24 hours significantly inhibited the release of IL-1β and CXCL1 by mouse bone marrow-derived macrophages (BMDMs) stimulated by monosodium urate (MSU) crystals[5]. Treatment with 20µM CD38 inhibitor 1 for 24 hours significantly induced the accumulation of extracellular cGAMP in ARH-77 cells[6].
In vivo, CD38 inhibitor 1 treatment via daily intraperitoneal injection at a dose of 10mg/kg twice a day for one month reduced white matter damage in the vascular dementia mouse model, improved cerebral blood flow, enhanced the expression of tight junction proteins in brain endothelial cells, and reduced neuroinflammation and blood-brain barrier (BBB) disruption[7].
References:
[1] Haffner C D, Becherer J D, Boros E E, et al. Discovery, synthesis, and biological evaluation of thiazoloquin (az) olin (on) es as potent CD38 inhibitors[J]. Journal of medicinal chemistry, 2015, 58(8): 3548-3571.
[2] Tarragó M G, Chini C C S, Kanamori K S, et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD+ decline[J]. Cell metabolism, 2018, 27(5): 1081-1095. e10.
[3] Boslett J, Reddy N, Alzarie Y A, et al. Inhibition of CD38 with the Thiazoloquin (az) olin (on) e 78c Protects the Heart against Postischemic Injury[J]. The Journal of pharmacology and experimental therapeutics, 2019, 369(1): 55-64.
[4] Ma J, Ying J, Wang J, et al. CD38 drives progress of osteoarthritis by affecting cartilage homeostasis[J]. Orthopaedic Surgery, 2022, 14(5): 946-954.
[5] Alabarse P G, Oliveira P, Qin H, et al. The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target[J]. Inflammation Research, 2024, 73(5): 739-751.
[6] Cuollo L, Di Cristofano S, Sandomenico A, et al. CD38 restrains the activity of extracellular cGAMP in a model of multiple myeloma[J]. IScience, 2024, 27(5).
[7] Yu M, Qi Z, Zhang J, et al. Targeting CD38 to alleviate brain endothelial cell dysfunction and cognitive impairment in vascular dementia[J]. Journal of Pharmacological Sciences, 2025, 158(4): 310-321.
CD38 inhibitor 1是一种强效的CD38抑制剂，对小鼠CD38的IC50值为1.9nM[1]。CD38 inhibitor 1可增加NAD+水平，从而激活多种与长寿和健康寿命相关的因子，如sirtuins、AMPK和PARPs，以预防代谢功能障碍[2]。CD38 inhibitor 1已被广泛用于保护心脏免受缺血损伤对内皮细胞和心肌细胞的损害[3]。
在体外，1µM的CD38 inhibitor 1处理小鼠软骨细胞14天，上调了Col2和聚集蛋白聚糖mRNA的表达，并促进了细胞分化[4]。50µM的CD38 inhibitor 1处理小鼠骨髓来源的巨噬细胞(BMDMs)24小时，显著抑制了尿酸单钠(MSU)晶体刺激诱导的IL-1β和CXCL1释放[5]。20µM的CD38 inhibitor 1处理ARH-77细胞24小时，显著诱导了细胞外cGAMP的积累[6]。
在体内，腹腔注射10mg/kg剂量的CD38 inhibitor 1，每日两次，持续一个月，减轻了血管性痴呆小鼠模型中的白质损伤，改善了脑血流量，增强了脑内皮细胞中紧密连接蛋白的表达，并减轻了神经炎症和血脑屏障(BBB)破坏[7]。
| Cell experiment [1]: | |
Cell lines | Mouse bone marrow-derived macrophages (BMDMs) |
Preparation Method | Mouse BMDMs were seeded in 6-well plates at a density of 1×104 cells in RPMI medium with 10% (v/v) fetal bovine serum (FBS), 100U/ml penicillin, and 100µg/ml streptomycin in a humidified atmosphere containing 5% CO2 for 24h. CD38 inhibitor 1 (50uM) and MSU crystals (0.2mg/ml) were treated for 24 hours. The conditioned media were used to quantify IL-1βand CXCL1 by ELISA analysis. |
Reaction Conditions | 50µM; 24h |
Applications | CD38 inhibitor 1 treatment significantly inhibited the release of IL-1β and CXCL1 by BMDMs stimulated by MSU crystals. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6 mice |
Preparation Method | Male C57BL/6 mice (8 weeks old; 22-25g) were housed in a room with controlled temperature (21-23°C), humidity (55-60%), and lighting (12h light/dark cycle) and were supplied with water. Mice were anesthetized using isoflurane and subsequently subjected to bilateral common carotid artery stenosis (BCAS), inducing chronic hypoperfusion through the application of microcoils (inner diameter of 0.18mm, pitch of 0.50mm, total length of 2.5mm). After the surgery, the incision site was meticulously closed, and the mice were provided with postoperative care until they regained consciousness and showed signs of recovery. Following this, they were allowed unrestricted access to food and water. The mice were employed and randomly divided into three groups (1) sham control (n=10), (2) BCAS+vehicle (n=12), and (3) BCAS+CD38 inhibitor 1 (intraperitoneal injection, 10mg/kg; twice daily, n=12) for 30 days. Collect the brain tissues of mice for analysis. |
Dosage form | 10mg/kg; twice daily for 30 days; i.p. |
Applications | CD38 inhibitor 1 treatment significantly reduced white matter damage and decreased neuroinflammation in mice induced by BCAS. |
References: | |
| Cas No. | 1700637-55-3 | SDF | Download SDF |
| 别名 | CD38-IN-78c, CD38 Inhibitor 78c | ||
| 分子式 | C22H27N3O3S | 分子量 | 413.53 |
| 溶解度 | DMSO : 25 mg/mL (60.46 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4182 mL | 12.091 mL | 24.182 mL |
| 5 mM | 483.6 μL | 2.4182 mL | 4.8364 mL |
| 10 mM | 241.8 μL | 1.2091 mL | 2.4182 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet